title: The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS).
abstract: OBJECTIVE
  To determine if EE/CA and EE/CA plus metformin treatment have any effect on adhesion molecules in cases with PCOS.
  
  
  METHODS
  Among 40 patients diagnosed with PCOS, one study arm was administered EE/CA (n=20, cyproterone acetate 2 mg, ethinylestradiol 35 microg) and the other was administered metformin (1,700 mg) combined with EE/CA (n=20, cyproterone acetate 2 mg, ethinylestradiol 35 microg). Soluble intercellular adhesion molecule-1 (sICAM-1), soluble endothelial leukocyte adhesion molecule-1 (sE-selectin), soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble leukocyte endothelial cell adhesion molecule-3 (sP-selectin), lipid profile, androgens, insulin, and HOMA-IR values were assessed prior to treatment and after 3 months of therapy.
  
  
  RESULTS
  The comparison of the groups receiving EE/CA and EE/CA+metformin revealed a significant reduction in sVCAM (1,445+/-614 vs 1,167+/-482, p<0.05) and sICAM (442+/-141 vs 345+/-118, p<0.05) values relative to pre-treatment values while no significant changes were detected in sE-selectin and sP-selectin levels relative to pre-treatment levels in the EE/CA+metformin group (p>0.05). In the post-treatment period, sVCAM, sICAM, sE-selectin values did not significantly change compared to the pre-treatment values in EE/CA group (p>0.05). sP-selectin levels were also decreased but missed the significance in EE/CA group (229.4+/-68.0 vs 189.6+/-65.0, p=0.08).
  
  
  CONCLUSIONS
  These results demonstrate that EE/CA+metformin treatment reduced inflammation markers in cases with PCOS compared to EE/CA treatment. The clinical relevance of this conclusion may be clarified by longer metformin treatment and clinical follow-up.
authors: Internal Medicine Division of Hematology, Bozyaka Training and Research Hospital, Izmir, Turkey. obilgir2001@yahoo.com
authors: Oktay
authors: O
authors: Bilgir
authors: Levent
authors: L
authors: Kebapcilar
authors: Cuneyt
authors: C
authors: Taner
authors: Ferda
authors: F
authors: Bilgir
authors: Ayse
authors: A
authors: Kebapcilar
authors: Giray
authors: G
authors: Bozkaya
authors: Yasar
authors: Y
authors: Yildiz
authors: Arif
authors: A
authors: Yuksel
authors: Ismail
authors: I
authors: Sari
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000187:drug effects*; D017373:Cyproterone Acetate / Q000494:pharmacology* / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000494:pharmacology* / Q000627:therapeutic use*; D004997:Ethinyl Estradiol / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D008687:Metformin / Q000494:pharmacology* / Q000627:therapeutic use*; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D015815:Cell Adhesion Molecules; D007004:Hypoglycemic Agents; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D004958:Estradiol; D008687:Metformin